FDA Approves Ribociclib for First-Line Metastatic Breast Cancer

The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Tags: Breast Cancer News Source Type: news